January 30, 2015 12:51 AM ET


Company Overview of Elcelyx Therapeutics, Inc.

Company Overview

Elcelyx Therapeutics, Inc. is a stealth mode company which operates in biotech sector. Its products are products based on the science of nutrient sensing. The company was incorporated in 2009 and is based in San Diego, California.

11995 El Camino Real

Suite 305

San Diego, CA 92130

United States

Founded in 2009



Key Executives for Elcelyx Therapeutics, Inc.

Chief Executive Officer
Age: 60
Executive Officer and Chairman
Age: 76
Executive Officer and Director
Chief Business Officer
Age: 67
Senior Vice President of Business Development
Age: 58
Compensation as of Fiscal Year 2014.

Elcelyx Therapeutics, Inc. Key Developments

Elcelyx Therapeutics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:55 AM

Elcelyx Therapeutics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:55 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Mark C. Wiggins, Senior Vice President of Business Development.

Elcelyx Therapeutics, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 02:25 PM

Elcelyx Therapeutics, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 02:25 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.

Elcelyx Therapeutics, Inc. Announces Positive Results in Phase 2B Study of NewMet in Type 2 Diabetes

Elcelyx Therapeutics, Inc. announced the completion of a 12-week Phase 2b study of NewMet(TM), a delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx previously reported that the study met its primary endpoint of statistically significant reduction in fasting plasma glucose at four weeks of treatment with NewMet compared to placebo. The 12-week data confirm the durability of the effect observed at four weeks. The randomized, 240-patient, multicenter, double-blind, dose-finding trial evaluated NewMet once-daily doses of 1000, 800 and 600 milligrams compared to placebo. There were also two unblinded reference arms with Glucophage(R) XR dosed once-daily at 1000 and 2000 milligrams. All NewMet arms showed efficacy comparable to or greater than 1000 milligrams of Glucophage XR. The NewMet 1000 milligram dose was approximately 50% more effective than 1000 milligrams of Glucophage XR and approximately 70% as effective as 2000 milligrams of Glucophage XR. A dose response trend was observed across the three NewMet doses, indicating higher doses of NewMet may provide greater efficacy. All doses of NewMet and Glucophage XR prevented the rise in HbA1c seen with placebo due to washout of previous anti-diabetic medications. All doses of NewMet and Glucophage XR were well tolerated and there were no meaningful weight changes observed. NewMet, which is targeted to the lower bowel, reduced systemic exposure by as much as 65% compared to metformin immediate release (IR) and metformin XR. The ability of NewMet to significantly reduce fasting plasma glucose over 12 weeks further confirms the durable efficacy of bowel-directed metformin. The dramatic reduction in plasma metformin exposure indicates that NewMet may be an appropriate treatment for Type 2 diabetes patients who have renal impairment and are contraindicated for metformin IR and metformin XR use due to the risk of lactic acidosis, a life-threatening condition that can result from metformin build-up in the blood.

Similar Private Companies By Industry

Company Name Region
OXYVITA Inc. United States
PharmaNutrients, Inc., CLA One Business United States
iDiverse, Inc. United States
Seragen, Inc. United States
King Pharmaceuticals Research & Development Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Elcelyx Therapeutics, Inc., please visit www.elcelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.